Memorandum – Core #230

To: UNC Health Attending Physicians, Faculty Practice Physicians, Housestaff, Clinical Nurse Coordinators, Department Heads and Supervisors

From: Nichole Korpi-Steiner, PhD, Director, Special Chemistry Laboratory
Herbert C. Whinna, MD, PhD, Medical Director, McLendon Laboratories

Date: January 7, 2026

Subject: Update to everolimus reference interval

Effective January 20th, 2026, in collaboration with pharmacy teammates the McLendon Laboratories Special Chemistry Lab will update the everolimus test reference interval to 3-8 ng/mL in order to better align with clinical practice and published literature [1]. The everolimus reference interval is for guidance only. Target stead-state trough concentrations vary depending on the type of transplant, concomitant immunosuppression, time post-transplant, and clinical / institutional protocols. Everolimus results should be interpreted in conjunction with this clinical information and any physical signs/symptoms of rejection or toxicity.

Test ID	Test Name	Current Reference Interval	New Reference Interval
LAB875A	Everolimus*	3-15 ng/mL	3-8 ng/mL

*Everolimus testing is performed by liquid chromatography tandem mass spectrometry.

Please contact Dr. Nichole Korpi-Steiner (Nichole.korpi-steiner@unchealth.unc.edu) for any technical questions.

References:
[1] Milone MC, Shaw LM. Therapeutic drugs and their management. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:800-831